Table 1 Demographic and clinicopathological characteristics of the patients at baseline
Characteristics | Chemotherapy (n = 57) | CBT (n = 25) | p value | ||
|---|---|---|---|---|---|
Number | % | Number | % | ||
Sex | |||||
Male | 35 | 61.40 | 15 | 60.00 | 1.00 |
Female | 22 | 38.60 | 10 | 40.00 | |
Age, years | |||||
<65 | 38 | 66.67 | 14 | 56.00 | 0.46 |
≥65 | 19 | 33.33 | 11 | 44.00 | |
Diagnosis basis | |||||
Pathologically | 29 | 50.88 | 14 | 56.00 | 0.81 |
Clinically | 28 | 49.12 | 11 | 44.00 | |
Extent of disease | |||||
Locally advanced | 9 | 15.79 | 2 | 8.00 | 0.49 |
Metastatic | 48 | 84.21 | 23 | 92.00 | |
Measurable metastatic sites | |||||
Livera | 30 | 52.63 | 13 | 52.00 | 1.00 |
Other | 27 | 47.37 | 12 | 48.00 | |
No. of metastatic sites | |||||
1 | 32 | 56.14 | 16 | 64.00 | 0.83 |
2 | 18 | 31.58 | 7 | 28.88 | |
≥3 | 7 | 12.28 | 2 | 8.00 | |
ECOG performance status score | |||||
1 | 20 | 35.09 | 9 | 36.00 | 1.00 |
2 | 37 | 64.91 | 16 | 64.00 | |
Pancreatic tumor location | |||||
Head | 21 | 36.84 | 14 | 56.00 | 0.17 |
Body | 5 | 8.78 | 4 | 16.00 | |
Tail | 16 | 28.07 | 3 | 12.00 | |
Multicentricb | 15 | 26.32 | 4 | 16.00 | |
Level of carbohydrate antigen 19-9 - u/ml | |||||
Abnormal | 47 | 82.46 | 20 | 80.00 | 0.23 |
Normal | 6 | 10.53 | 5 | 20.00 | |
Unknownc | 4 | 7.02 | 0 | 0.00 | |